Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Given New $22.00 Price Target at UBS Group

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) had its price objective boosted by UBS Group from $21.00 to $22.00 in a research note released on Monday,Benzinga reports. UBS Group currently has a buy rating on the stock.

Separately, William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.

Telix Pharmaceuticals Limited American Depositary Shares Trading Down 1.8 %

Telix Pharmaceuticals Limited American Depositary Shares stock opened at $17.92 on Monday. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $14.01 and a fifty-two week high of $19.99. The stock has a 50 day moving average price of $15.81.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.